Interview with Vadim Belevitskiy, General Manager, Lundbeck Russia
Lundbeck is a niche player exclusively focused on the treatment of CNS and mental health disorders. How developed do you find this niche to be in Russia? The size of…
Address: 2nd Krutitskiy Pereulok, 18, building 1 ,109044 Moscow ,Russia
Tel: +7 (495) 380 31 97
Web: http://www.lundbeck.com/ru
Our mission is to improve the quality of life of people suffering from mental and neurological diseases.
Vision: We aim to become the world leader in psychiatry and neurology.
Our fundamental beliefs:
Our strength – Specialization
Speed- our weapon
Integration – our goal
The results – an indicator of our success
Research – the backbone of our organization
Our values:
‘Openness, honesty, team spirit, mutual respect and integrity’
Lundbeck is the only pharmaceutical company in the world devoting its research activities exclusively to mental disorders and diseases of the central nervous system.
Specialists in psychiatry; pioneers in neurology
Lundbeck is a niche player exclusively focused on the treatment of CNS and mental health disorders. How developed do you find this niche to be in Russia? The size of…
IMEDA was founded in 2005, and today counts amongst its members 28 leading international companies in the Russian medical technology sector. What are the main goals of the association today,…
When we first met, you mentioned that you assumed this position in 2009, to help UCB Russia recover from a flat spin in the wake of the financial crisis. What…
Merck KGaA describes itself as the world’s oldest pharmaceutical and chemicals company. What is the company’s history here in Russia? The Russian subsidiary was actually incorporated over 100 years ago.…
Ipsen has recently announced the acquisition of a Russian pharmaceutical license. Even before this license, Russia was already one of the largest affiliates. of the group, as of 2010. The…
What were the difficulties in the CIS regions around the time of the financial crisis? Were there similarities to the situation in Russia? Yes, the situation in the CIS was…
You have been with Boehringer Ingelheim since the early days of your career in 1994. In the pharmaceutical sector, managers seem to jump from company to company quite often—but you…
You were the former director of RMBC, which was acquired in 2008 by the IMS. How important was this acquisition in terms of positioning the IMS on the Russian market?…
Roche is the leading company in the ONLS (high-technology reimbursement) segment of the prescription drug market, and also the top oncology company in Russia. As the General Manager of the…
You have been in Russia now for a bit less than a year, having come from the former Schering-Plough’s Hungary office to run the Russian MSD affiliate. In our conversation…
Binnopharm was established in 2006, with 100% of charter capital coming from holding company JSFC Sistema. What was the vision behind the creation of Binnopharm? The company was indeed established…
Nycomed is currently constructing a Greenfield plant in the Yaroslavl region, at an investment of 75-80Mn EUR. Last time we met in 2006, many foreign companies viewed local production as…
Celegene did not have a Russian affiliate office during Focus Reports’ initial report on Russia in 2006. What attracted Celgene’s relatively recent entrance into this market? We had external and…
See our Cookie Privacy Policy Here